



August 30, 2023

Restated Financial Disclosures

Table of Contents

<u>Table 1: Sales by Geographic Area - 2023</u>	1
<u>Table 1a: Sales by Geographic Area - 2022</u>	2
<u>Table 2: Condensed Consolidated Statement of Earnings - 2023</u>	3
<u>Table 2a: Condensed Consolidated Statement of Earnings - 2022</u>	4
<u>Table 3: Non-GAAP Adjusted Net Earnings - 2023</u>	5
<u>Table 3a: Non-GAAP Adjusted Net Earnings - 2022</u>	6
<u>Table 4: Non-GAAP Adjusted Operational Sales Growth - 2023</u>	7
<u>Table 4a: Non-GAAP Adjusted Operational Sales Growth - 2022</u>	8
<u>Table 5: Non-GAAP IBT by Segment - Q1 2023</u>	9
<u>Table 5a: Non-GAAP IBT by Segment - Q2 2023</u>	10
<u>Table 5b: Non-GAAP IBT by Segment - Q1 2022</u>	11
<u>Table 5c: Non-GAAP IBT by Segment - Q2 2022</u>	12
<u>Table 5d: Non-GAAP IBT by Segment - Q3 2022</u>	13
<u>Table 5e: Non-GAAP IBT by Segment - Q4 2022</u>	14
<u>Table 6: Non-GAAP P&L Reconciliation - 2023</u>	15
<u>Table 6a: Non-GAAP P&L Reconciliation - 2022</u>	16

Johnson & Johnson and Subsidiaries

Supplementary Sales Data

(Unaudited; Dollars in Millions)		FIRST QUARTER				
	2023	2022	Total	Percent Change		
				Operations	Currency	
Sales to customers by geographic area						
U.S.	\$ 10,782	9,857	9.4 %	9.4	-	
Europe	5,590	5,341	4.7	9.4	(4.7)	
Western Hemisphere excluding U.S.	1,076	998	7.8	15.5	(7.7)	
Asia-Pacific, Africa	3,446	3,644	(5.4)	3.1	(8.5)	
International	10,112	9,983	1.3	7.7	(6.4)	
Worldwide	\$ 20,894	19,840	5.3 %	8.5	(3.2)	

(Unaudited; Dollars in Millions)		SECOND QUARTER				
	2023	2022	Total	Percent Change		
				Operations	Currency	
Sales to customers by geographic area						
U.S.	\$ 11,657	10,510	10.9 %	10.9	-	
Europe	5,131	5,355	(4.2)	(5.2)	1.0	
Western Hemisphere excluding U.S.	1,136	1,027	10.7	16.8	(6.2)	
Asia-Pacific, Africa	3,595	3,323	8.2	14.3	(6.1)	
International	9,862	9,705	1.6	3.8	(2.2)	
Worldwide	\$ 21,519	20,215	6.5 %	7.5	(1.0)	

(Unaudited; Dollars in Millions)		SIX MONTHS				
	2023	2022	Total	Percent Change		
				Operations	Currency	
Sales to customers by geographic area						
U.S.	\$ 22,439	20,367	10.2 %	10.2	-	
Europe	10,721	10,696	0.2	2.1	(1.9)	
Western Hemisphere excluding U.S.	2,212	2,025	9.3	16.2	(6.9)	
Asia-Pacific, Africa	7,041	6,967	1.1	8.5	(7.4)	
International	19,974	19,688	1.5	5.8	(4.3)	
Worldwide	\$ 42,413	40,055	5.9 %	8.0	(2.1)	

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely

Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)						
FIRST QUARTER						
			Percent Change			
		2022	2021	Total	Operations	Currency
Sales to customers by geographic area						
U.S.	\$	9,857	9,500	3.8 %	3.8	-
Europe		5,341	4,727	13.0	21.2	(8.2)
Western Hemisphere excluding U.S.		998	968	3.0	4.2	(1.2)
Asia-Pacific, Africa		3,644	3,485	4.6	8.3	(3.7)
International		9,983	9,180	8.7	14.5	(5.8)
Worldwide	\$	19,840	18,680	6.2 %	9.1	(2.9)

(Unaudited; Dollars in Millions)						
SECOND QUARTER						
			Percent Change			
		2022	2021	Total	Operations	Currency
Sales to customers by geographic area						
U.S.	\$	10,510	10,168	3.4 %	3.4	-
Europe		5,355	4,936	8.5	22.1	(13.6)
Western Hemisphere excluding U.S.		1,027	933	10.2	13.2	(3.0)
Asia-Pacific, Africa		3,323	3,421	(2.9)	6.2	(9.1)
International		9,705	9,290	4.5	15.4	(10.9)
Worldwide	\$	20,215	19,458	3.9 %	9.1	(5.2)

(Unaudited; Dollars in Millions)						
THIRD QUARTER						
			Percent Change			
		2022	2021	Total	Operations	Currency
Sales to customers by geographic area						
U.S.	\$	10,794	10,338	4.4 %	4.4	-
Europe		4,844	4,833	0.2	16.1	(15.9)
Western Hemisphere excluding U.S.		1,059	1,019	3.9	9.1	(5.2)
Asia-Pacific, Africa		3,299	3,336	(1.1)	11.4	(12.5)
International		9,202	9,188	0.1	13.6	(13.5)
Worldwide	\$	19,996	19,526	2.4 %	8.7	(6.3)

(Unaudited; Dollars in Millions)						
FOURTH QUARTER						
			Percent Change			
		2022	2021	Total	Operations	Currency
Sales to customers by geographic area						
U.S.	\$	10,820	10,634	1.7 %	1.7	-
Europe		5,124	6,099	(16.0)	(6.3)	(9.7)
Western Hemisphere excluding U.S.		1,024	1,007	1.7	8.3	(6.6)
Asia-Pacific, Africa		2,971	3,336	(10.9)	3.0	(13.9)
International		9,119	10,442	(12.7)	(1.9)	(10.8)
Worldwide	\$	19,939	21,076	(5.4) %	(0.1)	(5.3)

(Unaudited; Dollars in Millions)						
TWELVE MONTHS						
			Percent Change			
		2022	2021	Total	Operations	Currency
Sales to customers by geographic area						
U.S.	\$	41,981	40,640	3.3 %	3.3	-
Europe		20,664	20,595	0.3	12.1	(11.8)
Western Hemisphere excluding U.S.		4,108	3,927	4.6	8.7	(4.1)
Asia-Pacific, Africa		13,237	13,578	(2.5)	7.2	(9.7)
International		38,009	38,100	(0.2)	10.0	(10.2)
Worldwide	\$	79,990	78,740	1.6 %	6.5	(4.9)

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)

2023

	Q1		Q2		SIX MONTHS	
	Amount	Percent to Sales	Amount	Percent to Sales	Amount	Percent to Sales
Sales to customers	\$ 20,894	100.0	\$ 21,519	100.0	\$ 42,413	100.0
Cost of products sold	6,687	32.0	6,462	30.0	13,149	31.0
Gross Profit	14,207	68.0	15,057	70.0	29,264	69.0
Selling, marketing and administrative expenses	4,906	23.5	5,396	25.1	10,302	24.3
Research and development expense	3,455	16.6	3,703	17.2	7,158	16.9
In-process research and development Impairments	49	0.2	-	-	49	0.1
Interest income	(198)	(0.9)	(326)	(1.5)	(524)	(1.2)
Interest expense, net of portion capitalized	212	1.0	217	1.0	429	1.0
Other (income) expense, net	6,940	33.2	(384)	(1.8)	6,556	15.5
Restructuring	130	0.6	145	0.7	275	0.6
Earnings/(loss) before provision for taxes on income	(1,287)	(6.2)	6,306	29.3	5,019	11.8
Provision for/(Benefit from) taxes on income	(796)	(3.9)	930	4.3	134	0.3
Net earnings/(loss) from Continuing Operations	\$ (491)	(2.3)	\$ 5,376	25.0	\$ 4,885	11.5
Net earnings/(loss) from Discontinued Operations, net of tax	423		(232)		191	
Net earnings/(loss)	\$ (68)		\$ 5,144		\$ 5,076	
Net Earnings (loss) per Share (Diluted) from Continuing Operations	\$ (0.19)		\$ 2.05		\$ 1.86	
Net Earnings (loss) per Share (Diluted) from Discontinued Operations	\$ 0.16		\$ (0.09)		\$ 0.07	
Average shares outstanding (Diluted)	2,605.5 *		2,625.7		2,630.7	
Effective tax rate from Continuing Operations	61.8 %		14.7 %		2.7 %	

*Basic Shares used as in an overall loss position

Adjusted earnings from continuing operations before provision for taxes and net earnings (1)						
Earnings before provision for taxes on income from continuing operations	\$ 7,536	36.1	\$ 8,005	37.2	\$ 15,541	36.6
Net earnings from continuing operations	\$ 6,340	30.3	\$ 6,730	31.3	\$ 13,070	30.8
Net earnings per share (Diluted) from continuing operations	\$ 2.41		\$ 2.56		\$ 4.97	
Average shares outstanding (Diluted)	2,634.3		2,625.7		2,630.7	
Effective tax rate from continuing operations	15.9 %		15.9 %		15.9 %	

(1) See Reconciliation of Non-GAAP Financial Measures.

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)

2022

	Q1		Q2		SIX MONTHS		Q3		Q4		FULL YEAR	
	Amount	Percent	Amount	Percent	Amount	Percent	Amount	Percent	Amount	Percent	Amount	Percent
		to Sales		to Sales		to Sales		to Sales		to Sales		to Sales
Sales to customers	\$ 19,840	100.0	\$ 20,215	100.0	\$ 40,055	100.0	\$ 19,996	100.0	\$ 19,939	100.0	\$ 79,990	100.0
Cost of products sold	6,018	30.3	6,322	31.3	12,340	30.8	6,172	30.9	6,084	30.5	24,596	30.7
Gross Profit	13,822	69.7	13,893	68.7	27,715	69.2	13,824	69.1	13,855	69.5	55,394	69.3
Selling, marketing and administrative expenses	4,812	24.3	5,120	25.3	9,932	24.8	4,975	24.9	5,339	26.8	20,246	25.3
Research and development expense	3,355	16.9	3,585	17.7	6,940	17.3	3,485	17.4	3,710	18.6	14,135	17.7
In-process research and development impairments	610	3.1	-	-	610	1.5	-	-	173	0.8	783	1.0
Interest income	(22)	(0.1)	(64)	(0.3)	(86)	(0.2)	(150)	(0.8)	(254)	(1.3)	(490)	(0.6)
Interest expense, net of portion capitalized	10	0.1	38	0.2	48	0.1	51	0.3	177	0.9	276	0.3
Other (income) expense, net	(210)	(1.1)	(1)	0.0	(211)	(0.5)	226	1.1	795	4.0	810	1.0
Restructuring	64	0.3	71	0.4	135	0.4	65	0.3	75	0.4	275	0.4
Earnings before provision for taxes on income	5,203	26.2	5,144	25.4	10,347	25.8	5,172	25.9	3,840	19.3	19,359	24.2
Provision for taxes on income	632	3.2	882	4.3	1,514	3.7	862	4.3	613	3.1	2,989	3.7
Net earnings from Continuing Operations	4,571	23.0	\$ 4,262	21.1	\$ 8,833	22.1	\$ 4,310	21.6	\$ 3,227	16.2	\$ 16,370	20.5
Net earnings from Discontinued Operations, net of tax	578		552		1,130		148		293		1,571	
Net earnings	\$ 5,149		\$ 4,814		\$ 9,963		\$ 4,458		\$ 3,520		\$ 17,941	
Net Earnings per Share (Diluted) from Continuing Operations	\$ 1.71		\$ 1.60		\$ 3.31		\$ 1.62		\$ 1.22		\$ 6.14	
Net Earnings per Share (Diluted) from Discontinued Operations	\$ 0.22		\$ 0.20		\$ 0.42		\$ 0.06		\$ 0.11		\$ 0.59	
Average shares outstanding (Diluted)	2,666.5		2,667.9		2,669.2		2,661.3		2,650.1		2,663.9	
Effective tax rate from Continuing Operations	12.1 %		17.1 %		14.6 %		16.7 %		16.0 %		15.4 %	
Adjusted earnings from continuing operations before provision for taxes and net earnings (1)												
Earnings before provision for taxes on income from continuing operations	\$ 7,349	37.0	\$ 7,082	35.0	\$ 14,431	36.0	\$ 7,060	35.3	\$ 6,482	32.5	\$ 27,973	35.0
Net earnings from continuing operations	\$ 6,388	32.2	\$ 6,038	29.9	\$ 12,426	31.0	\$ 5,938	29.7	\$ 5,432	27.2	\$ 23,796	29.7
Net earnings per share (Diluted) from continuing operations	\$ 2.40		\$ 2.26		\$ 4.66		\$ 2.23		\$ 2.05		\$ 8.93	
Average shares outstanding (Diluted)	2,666.5		2,667.9		2,669.2		2,661.3		2,650.1		2,663.9	
Effective tax rate from continuing operations	13.1 %		14.7 %		13.9 %		15.9 %		16.2 %		14.9 %	

(1) See Reconciliation of Non-GAAP Financial Measures.

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

(Dollars in Millions Except Per Share Data)	2023		
	Q1	Q2	SIX MONTHS
Net Earnings/(loss) from Continuing Operations, after tax - as reported	(\$491)	\$5,376	\$4,885
<i>Pre-tax Adjustments</i>			
Intangible Asset Amortization expense	1,122	1,130	2,252
Litigation related	6,900	137	7,037
IPR&D impairments	49	0	49
Restructuring related	130	145	275
Acquisition, integration and divestiture related	42	38	80
(Gains)/losses on securities	72	(1)	71
Medical Device Regulation	64	85	149
COVID-19 Vaccine related costs	444	165	609
<i>Tax Adjustments</i>			
Tax impact on special item adjustments	(1,980)	(307)	(2,287)
Consumer Health separation tax related costs	11	(17)	(6)
Tax legislation and other tax related	(23)	(21)	(44)
Adjusted Net Earnings from continuing operations, after tax	\$6,340	\$6,730	\$13,070
Average shares outstanding (Diluted)	2,634.3	2,625.7	2,630.7
Adjusted net earnings per share from continuing operations (Diluted)	\$2.41	\$2.56	\$4.97

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

(Dollars in Millions Except Per Share Data)	2022				
	Q1	Q2	Q3	Q4	FULL YEAR
Net Earnings from Continuing Operations, after tax - as reported	\$4,571	\$4,262	\$4,310	\$3,227	\$16,370
<i>Pre-tax Adjustments</i>					
Intangible Asset Amortization expense	1,014	995	958	977	3,944
Litigation related	0	385	219	262	866
IPR&D impairments	610	0	0	173	783
Restructuring related	58	103	92	119	372
Acquisition, integration and divestiture related	0	0	0	196	196
(Gains)/losses on securities	411	109	164	6	690
Medical Device Regulation	60	70	78	88	296
COVID-19 Vaccine related costs	0	276	377	821	1,474
Other	(7)	0	0	0	(7)
<i>Tax Adjustments</i>					
Tax impact on special item adjustments	(346)	(242)	(312)	(394)	(1,294)
Consumer Health separation tax related costs	96	2	(36)	4	66
Tax legislation and other tax related	(79)	78	88	(47)	40
Adjusted Net Earnings from continuing operations, after tax	\$6,388	\$6,038	\$5,938	\$5,432	\$23,796
Average shares outstanding (Diluted)	2,666.5	2,667.9	2,661.3	2,650.1	2,663.9
Adjusted net earnings per share from continuing operations (Diluted)	\$2.40	\$2.26	\$2.23	\$2.05	\$8.93

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure

Adjusted Operational Sales Growth
2023 ACTUAL vs. 2022 ACTUAL

Total Enterprise

	<u>Q1</u>	<u>Q2</u>	<u>SIX MONTHS</u>
WW As Reported	5.3%	6.5%	5.9%
U.S.	9.4%	10.9%	10.2%
International	1.3%	1.6%	1.5%
WW Currency	(3.2)	(1.0)	(2.1)
U.S.	-	-	-
International	(6.4)	(2.2)	(4.3)
WW Operational	8.5%	7.5%	8.0%
U.S.	9.4%	10.9%	10.2%
International	7.7%	3.8%	5.8%
Abiomed	(1.6)	(1.6)	(1.6)
U.S.	(2.7)	(2.6)	(2.6)
International	(0.6)	(0.6)	(0.6)
All Other Acquisitions and Divestitures	0.0	0.1	0.0
U.S.	0.0	0.0	0.0
International	0.1	0.2	0.2
WW Adjusted Operational	6.9%	6.0%	6.4%
U.S.	6.7%	8.3%	7.6%
International	7.2%	3.4%	5.4%

Note: Percentages are based on actual, non-rounded figures and may not sum

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure

Adjusted Operational Sales Growth
2022 ACTUAL vs. 2021 ACTUAL

Total Enterprise							
	<u>Q1</u>	<u>Q2</u>	<u>SIX MONTHS</u>	<u>Q3</u>	<u>NINE MONTHS</u>	<u>Q4</u>	<u>TWELVE MONTHS</u>
WW As Reported	6.2%	3.9%	5.0%	2.4%	4.1%	(5.4)%	1.6%
U.S.	3.8%	3.4%	3.6%	4.4%	3.8%	1.7%	3.3%
International	8.7%	4.5%	6.6%	0.1%	4.5%	(12.7)%	(0.2)%
WW Currency	(2.9)	(5.2)	(4.1)	(6.3)	(4.8)	(5.3)	(4.9)
U.S.	-	-	-	-	-	-	-
International	(5.8)	(10.9)	(8.4)	(13.5)	(10.0)	(10.8)	(10.2)
WW Operational	9.1%	9.1%	9.1%	8.7%	8.9%	(0.1)%	6.5%
U.S.	3.8%	3.4%	3.6%	4.4%	3.8%	1.7%	3.3%
International	14.5%	15.4%	15.0%	13.6%	14.5%	(1.9)%	10.0%
Abiomed						(0.1)	
U.S.						(0.3)	
International						0.0	
All Other Acquisitions and Divestitures	0.0	0.1	0.1	0.1	0.1	0.1	0.0
U.S.	0.0	0.1	0.0	0.1	0.0	0.1	0.0
International	0.0	0.1	0.1	0.1	0.1	0.1	0.1
WW Adjusted Operational	9.1%	9.2%	9.2%	8.8%	9.0%	(0.1)%	6.5%
U.S.	3.8%	3.5%	3.6%	4.5%	3.8%	1.5%	3.3%
International	14.5%	15.5%	15.1%	13.7%	14.6%	(1.8)%	10.1%

Note: Percentages are based on actual, non-rounded figures and may not sum

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

Q1 2023 - Income Before Tax by Segment from Continuing Operations
Dollars in Millions

	<u>Pharmaceutical</u>	<u>MedTech</u>	<u>Unallocated</u>	<u>Worldwide Total</u>
Reported Income Before Tax by Segment from Continuing Operations	\$ 4,402	1,409	(7,098)	(1,287)
% to Sales	32.8%	18.8%	-34.0%	-6.2%
Intangible asset amortization expense	739	383	-	1,122
In-process research and development Impairments	-	49	-	49
Litigation Related	-	-	6,900	6,900
Loss/(gain) on securities	38	34	-	72
Restructuring related	130	-	-	130
Acquisition, integration and divestiture related	-	42	-	42
Medical Device Regulation	-	64	-	64
COVID-19 Vaccine related costs	444	-	-	444
Adjusted Income Before Tax by Segment from Continuing Operations	\$ <u>5,753</u>	<u>1,981</u>	<u>(198)</u>	<u>7,536</u>
% to Sales	<u>42.9%</u>	<u>26.5%</u>	<u>-0.9%</u>	<u>36.1%</u>

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

Q2 2023 QTD - Income Before Tax by Segment from Continuing Operations
Dollars in Millions

	Pharmaceutical	MedTech	Unallocated	Worldwide Total
Reported Income Before Tax by Segment from Continuing Operations	\$ 4,812	1,671	(177)	6,306
% to Sales	35.0%	21.5%	-0.8%	29.3%
Intangible asset amortization expense	748	382	-	1,130
In-process research and development Impairments	-	-	-	-
Litigation Related	(93)	60	170	137
Loss/(gain) on securities	38	(39)	-	(1)
Restructuring related	145	-	-	145
Acquisition, integration and divestiture related	-	38	-	38
Medical Device Regulation	-	85	-	85
COVID-19 Vaccine related costs	165	-	-	165
Adjusted Income Before Tax by Segment from Continuing Operations	\$ 5,815	2,197	(7)	8,005
% to Sales	42.3%	28.2%	0.0%	37.2%

Q2 2023 YTD - Income Before Tax by Segment from Continuing Operations
Dollars in Millions

	Pharmaceutical	MedTech	Unallocated	Worldwide Total
Reported Income Before Tax by Segment from Continuing Operations	\$ 9,214	3,080	(7,275)	5,019
% to Sales	33.9%	20.2%	-17.2%	11.8%
Intangible asset amortization expense	1,487	765	-	2,252
In-process research and development Impairments	-	49	-	49
Litigation Related	(93)	60	7,070	7,037
Loss/(gain) on securities	76	(5)	-	71
Restructuring related	275	-	-	275
Acquisition, integration and divestiture related	-	80	-	80
Medical Device Regulation	-	149	-	149
COVID-19 Vaccine related costs	609	-	-	609
Adjusted Income Before Tax by Segment from Continuing Operations	\$ 11,568	4,178	(205)	15,541
% to Sales	42.6%	27.4%	-0.5%	36.6%

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

Q1 2022 - Income Before Tax by Segment from Continuing Operations
Dollars in Millions

	<u>Pharmaceutical</u>	<u>MedTech</u>	<u>Unallocated</u>	<u>Worldwide Total</u>
Reported Income Before Tax by Segment from Continuing Operations	\$ 3,873	1,441	(111)	5,203
% to Sales	30.1%	20.7%	-0.6%	26.2%
Intangible asset amortization expense	760	254	-	1,014
In-process research and development Impairments	610	-	-	610
Loss/(gain) on securities	394	17	-	411
Restructuring related	(14)	72	-	58
Medical Device Regulation	-	60	-	60
Other	-	-	(7)	(7)
Adjusted Income Before Tax by Segment from Continuing Operations	<u>\$ 5,623</u>	<u>1,844</u>	<u>(118)</u>	<u>7,349</u>
% to Sales	43.7%	26.5%	-0.6%	37.0%

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

Q2 2022 QTD - Income Before Tax by Segment from Continuing Operations
Dollars in Millions

	<u>Pharmaceutical</u>	<u>MedTech</u>	<u>Unallocated</u>	<u>Worldwide Total</u>
Reported Income Before Tax by Segment from Continuing Operations <i>% to Sales</i>	\$ 4,365 32.8%	1,110 16.1%	(331) -1.6%	5,144 25.4%
Intangible asset amortization expense	736	259	-	995
Litigation Related	21	264	100	385
Loss/(gain) on securities	102	7	-	109
Restructuring related	23	80	-	103
Medical Device Regulation	-	70	-	70
COVID-19 Vaccine related costs	276	-	-	276
Adjusted Income Before Tax by Segment from Continuing Operations <i>% to Sales</i>	<u>\$ 5,523</u> 41.5%	<u>1,790</u> 25.9%	<u>(231)</u> -1.1%	<u>7,082</u> 35.0%

Q2 2022 YTD - Income Before Tax by Segment from Continuing Operations
Dollars in Millions

	<u>Pharmaceutical</u>	<u>MedTech</u>	<u>Unallocated</u>	<u>Worldwide Total</u>
Reported Income Before Tax by Segment from Continuing Operations <i>% to Sales</i>	\$ 8,238 31.5%	2,551 18.4%	(442) -1.1%	10,347 25.8%
Intangible asset amortization expense	1,496	513	-	2,009
In-process research and development Impairments	610	-	-	610
Litigation Related	21	264	100	385
Loss/(gain) on securities	496	24	-	520
Restructuring related	9	152	-	161
Medical Device Regulation	-	130	-	130
COVID-19 Vaccine related costs	276	-	-	276
Other	-	-	(7)	(7)
Adjusted Income Before Tax by Segment from Continuing Operations <i>% to Sales</i>	<u>\$ 11,146</u> 42.6%	<u>3,634</u> 26.2%	<u>(349)</u> -0.9%	<u>14,431</u> 36.0%

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

Q3 2022 QTD - Income Before Tax by Segment from Continuing Operations
Dollars in Millions

	<u>Pharmaceutical</u>	<u>MedTech</u>	<u>Unallocated</u>	<u>Worldwide Total</u>
Reported Income Before Tax by Segment from Continuing Operations <i>% to Sales</i>	\$ 4,186 31.7%	1,090 16.1%	(104) -0.5%	5,172 25.9%
Intangible asset amortization expense	698	260	-	958
Litigation Related	7	212	-	219
Loss/(gain) on securities	177	(13)	-	164
Restructuring related	23	69	-	92
Medical Device Regulation	-	78	-	78
COVID-19 Vaccine related costs	377	-	-	377
Adjusted Income Before Tax by Segment from Continuing Operations <i>% to Sales</i>	<u>\$ 5,468</u> 41.4%	<u>1,696</u> 25.0%	<u>(104)</u> -0.5%	<u>7,060</u> 35.3%

Q3 2022 YTD - Income Before Tax by Segment from Continuing Operations
Dollars in Millions

	<u>Pharmaceutical</u>	<u>MedTech</u>	<u>Unallocated</u>	<u>Worldwide Total</u>
Reported Income Before Tax by Segment from Continuing Operations <i>% to Sales</i>	\$ 12,424 31.5%	3,641 17.6%	(546) -0.9%	15,519 25.8%
Intangible asset amortization expense	2,194	773	-	2,967
In-process research and development Impairments	610	-	-	610
Litigation Related	28	476	100	604
Loss/(gain) on securities	673	11	-	684
Restructuring related	32	221	-	253
Medical Device Regulation	-	208	-	208
COVID-19 Vaccine related costs	653	-	-	653
Other	-	-	(7)	(7)
Adjusted Income Before Tax by Segment from Continuing Operations <i>% to Sales</i>	<u>\$ 16,614</u> 42.2%	<u>5,330</u> 25.8%	<u>(453)</u> -0.8%	<u>21,491</u> 35.8%

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

Q4 2022 QTD - Income Before Tax by Segment from Continuing Operations
Dollars in Millions

	Pharmaceutical	MedTech	Unallocated	Worldwide Total
Reported Income Before Tax by Segment from Continuing Operations	\$ 3,223	806	(189)	3,840
% to Sales	24.5%	11.9%	-0.9%	19.3%
Intangible asset amortization expense	717	260	-	977
In-process research and development Impairments	173	-	-	173
Litigation Related	76	136	50	262
Loss/(gain) on securities	23	(17)	-	6
Restructuring related	31	88	-	119
Acquisition, integration and divestiture related	(104)	300	-	196
Medical Device Regulation	-	88	-	88
COVID-19 Vaccine related costs	821	-	-	821
Adjusted Income Before Tax by Segment from Continuing Operations	<u>\$ 4,960</u>	<u>1,661</u>	<u>(139)</u>	<u>6,482</u>
% to Sales	37.7%	24.5%	-0.7%	32.5%

Q4 2022 YTD - Income Before Tax by Segment from Continuing Operations
Dollars in Millions

	Pharmaceutical	MedTech	Unallocated	Worldwide Total
Reported Income Before Tax by Segment from Continuing Operations	\$ 15,647	4,447	(735)	19,359
% to Sales	29.8%	16.2%	-0.9%	24.2%
Intangible asset amortization expense	2,911	1,033	-	3,944
In-process research and development Impairments	783	-	-	783
Litigation Related	104	612	150	866
Loss/(gain) on securities	696	(6)	-	690
Restructuring related	63	309	-	372
Acquisition, integration and divestiture related	(104)	300	-	196
Medical Device Regulation	-	296	-	296
COVID-19 Vaccine related costs	1,474	-	-	1,474
Other	-	-	(7)	(7)
Adjusted Income Before Tax by Segment from Continuing Operations	<u>\$ 21,574</u>	<u>6,991</u>	<u>(592)</u>	<u>27,973</u>
% to Sales	41.0%	25.5%	-0.7%	35.0%

Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
\$ in Millions

Quarter to Date	First Quarter	Intangible asset	Litigation related	In-process	Restructuring	Acquisition,	(Loss)/gain on	Medical Device	COVID-19 Vaccine	Consumer Health	Tax legislation and	First Quarter
	April 2, 2023											amortization
	GAAP			development		divestiture related				related costs		Non-GAAP
Cost of products sold	\$ 6,687	(1,118)		Impairments	-				(23)	(206)		5,340
Selling, marketing and admin expenses	4,906								(7)			4,899
Research and development expense	3,455					(16)			(34)	(16)		3,389
Other (Income) / Expense	6,940	(4)	(6,900)		-	(26)	(72)			(222)		(284)
In-process research and development Impairments	49			(49)								-
Interest (Income) / Expense	14											14
Restructuring	130				(130)							-
Provision for/(Benefit from) taxes on income	(796)	177	1,622	11	32	5	16	12	105	(11)	23	1,196
Net Earnings/(Loss) from Continuing Operations	(491)	945	5,278	38	98	37	56	52	339	11	(23)	6,340
Quarter to Date												
	Second Quarter	Intangible asset	Litigation related	In-process	Restructuring	Acquisition,	(Loss)/gain on	Medical Device	COVID-19 Vaccine	Consumer Health	Tax legislation and	Second Quarter
	July 2, 2023											amortization
	GAAP			development		divestiture related				related costs		Non-GAAP
Cost of products sold	\$ 6,462	(1,130)		Impairments	-				(34)	38	-	5,336
Selling, marketing and admin expenses	5,396								(8)			5,388
Research and development expense	3,703					-			(44)	(46)		3,613
Other (Income) / Expense	(384)	-	(137)		-	(38)	1			(156)	-	(714)
In-process research and development Impairments	-			-								-
Interest (Income)/Expense	(109)											(109)
Restructuring	145				(145)							-
Provision for taxes on income	930	177	29	-	37	12	(1)	15	38	17	21	1,275
Net Earnings from Continuing Operations	5,376	953	108	-	108	26	-	71	126	(17)	(21)	6,730
Year to Date												
	Six Months	Intangible asset	Litigation related	In-process	Restructuring	Acquisition,	(Loss)/gain on	Medical Device	COVID-19 Vaccine	Consumer Health	Tax legislation and	Six Months
	July 2, 2023											amortization
	GAAP			development		divestiture related				related costs		Non-GAAP
Cost of products sold	\$ 13,149	(2,248)		Impairments	-				(57)	(168)		10,676
Selling, marketing and admin expenses	10,302								(15)			10,287
Research and development expense	7,158					(16)				(62)		7,002
Other (Income) / Expense	6,556	(4)	(7,037)		-	(64)	(71)		(78)		-	(998)
In-process research and development Impairments	49			(49)		-						-
Interest (Income)/Expense	(95)											(95)
Restructuring	275				(275)							-
Provision for taxes on income	134	354	1,651	11	69	17	15	27	143	6	44	2,471
Net Earnings from Continuing Operations	4,885	1,898	5,386	38	206	63	56	123	465	(6)	(44)	13,070

Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
 \$ in Millions

Quarter to Date	Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation \$ in Millions											First Quarter April 3, 2022 Non-GAAP	
	First Quarter April 3, 2022 GAAP	Intangible asset amortization	Litigation related	In-process research and development Impairments	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Medical Device Regulation	COVID-19 Vaccine Related Costs	Consumer Health separation tax related costs	Tax legislation and other tax related		Other
Cost of products sold	\$ 6,018	(1,014)			(14)			(22)					4,968
Selling, marketing and admin expenses	4,812						(6)						4,806
Research and development expense	3,355						(32)						3,323
Other (Income) / Expense	(210)				20							7	(594)
In-process research and development Impairments	610			(610)			(411)						-
Restructuring	64				(64)								-
Provision for taxes on income	632	148	(53)	138	8		96	11		(96)	79	(2)	961
Net Earnings from Continuing Operations	4,571	866	53	472	50		315	49		96	(79)	(5)	6,388
Quarter to Date	Second Quarter July 3, 2022 GAAP	Intangible asset amortization	Litigation related	In-process research and development Impairments	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Medical Device Regulation	COVID-19 Vaccine Related Costs	Consumer Health separation tax related costs	Tax legislation and other tax related	Other	Second Quarter July 3, 2022 Non-GAAP
Cost of products sold	\$ 6,322	(995)			(14)			(25)	(194)	-	-	-	5,094
Selling, marketing and admin expenses	5,120							(6)					5,114
Research and development expense	3,585							(39)	(110)				3,436
Other (Income) / Expense	(1)		(385)		(18)		(109)		28				(485)
In-process research and development Impairments	-			-									-
Restructuring	71				(71)								-
Provision for taxes on income	882	148	(29)	-	20		25	13	65	(2)	(78)	-	1,044
Net Earnings from Continuing Operations	4,262	847	414	-	83		84	57	211	2	78	-	6,038
Quarter to Date	Third Quarter Oct 2, 2022 GAAP	Intangible asset amortization	Litigation related	In-process research and development Impairments	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Medical Device Regulation	COVID-19 Vaccine Related Costs	Consumer Health separation tax related costs	Tax legislation and other tax related	Other	Third Quarter Oct 2, 2022 Non-GAAP
Cost of products sold	\$ 6,172	(958)			(9)			(29)	(102)	-	-	-	5,074
Selling, marketing and admin expenses	4,975							(7)					4,968
Research and development expense	3,485							(42)	(80)				3,363
Other (Income) / Expense	226		(219)		(18)		(164)		(195)				(370)
In-process research and development Impairments	-			-									-
Restructuring	65				(65)								-
Provision for taxes on income	862	146	(7)	-	19		43	15	96	36	(88)	-	1,122
Net Earnings from Continuing Operations	4,310	812	226	-	73		121	63	281	(36)	88	-	5,938
Quarter to Date	Fourth Quarter Jan 1, 2023 GAAP	Intangible asset amortization	Litigation related	In-process research and development Impairments	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Medical Device Regulation	COVID-19 Vaccine Related Costs	Consumer Health separation tax related costs	Tax legislation and other tax related	Other	Fourth Quarter Jan 1, 2023 Non-GAAP
Cost of products sold	\$ 6,084	(977)			(25)			(33)	(160)	-	-	-	4,889
Selling, marketing and admin expenses	5,339							(9)					5,330
Research and development expense	3,710							(46)	(114)				3,550
Other (Income) / Expense	795		(262)		(19)		(6)		(547)				(235)
In-process research and development Impairments	173			(173)									-
Restructuring	75				(75)								-
Provision for taxes on income	613	148	(36)	40	19		2	17	199	(4)	47	-	1,050
Net Earnings from Continuing Operations	3,227	829	298	133	100	191	4	71	622	4	(47)	-	5,432
Year to Date	Twelve Months Jan 1, 2023 GAAP	Intangible asset amortization	Litigation related	In-process research and development Impairments	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Medical Device Regulation	COVID-19 Vaccine Related Costs	Consumer Health separation tax related costs	Tax legislation and other tax related	Other	Twelve Months Jan 1, 2023 Non-GAAP
Cost of products sold	\$ 24,596	(3,944)			(62)			(109)	(456)				20,025
Selling, marketing and admin expenses	20,246							(28)					20,218
Research and development expense	14,135							(159)	(304)				13,672
Other (Income) / Expense	810		(866)		(35)	(196)	(690)		(714)			7	(1,684)
In-process research and development Impairments	783			(783)									-
Restructuring	275				(275)								-
Provision for taxes on income	2,989	590	(125)	178	66	5	166	56	360	(66)	(40)	(2)	4,177
Net Earnings from Continuing Operations	16,370	3,354	991	605	306	191	524	240	1,114	66	40	(5)	23,796